Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

Advanced upper tract urothelial carcinoma (UTUC) has different molecular and genetic features from the commonest carcinoma of the bladder, suggesting a possible different sensitivity to immune-checkpoint inhibitors (ICI).